Contents▾
This content is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before making any health decisions.
BPC-157 is not a controlled substance under US law, and it is not FDA-approved. It doesn't fit cleanly into any standard regulatory category — which is exactly why the question "is it legal?" produces conflicting answers. The honest answer is that legality depends on which of two regulatory tracks your provider operates on. Two separate supply chains for BPC-157 exist simultaneously in the US: a licensed compounding pharmacy route requiring a valid prescription, and a research chemical vendor route that does not. Which track your provider is on shapes your regulatory exposure.
- BPC-157 is not scheduled as a controlled substance and has no FDA-approved use — it exists in a regulatory gap between drug and research compound.
- Two US supply chains operate simultaneously: 503A compounding pharmacies (prescription required, state-licensed oversight) and research chemical vendors ("for laboratory use only" labeling, no prescription required).
- The prescription requirement is the clearest single indicator of which track a provider is on.
- 415 active US providers list BPC-157 in the PeptideBase directory (May 2026). 85% are clinics operating through a patient-provider relationship.
- Federal status is only half the picture — state pharmacy board rules add a second regulatory layer that varies meaningfully across states.
- "Legal to operate" and "quality-controlled" are separate questions — the regulatory track describes legal exposure, not product purity.
BPC-157's regulatory status: neither approved nor scheduled
BPC-157 on PeptideBase
Evidence grades, provider availability, and research signals.
BPC-157 (Body Protection Compound-157) is a synthetic peptide that has been the subject of animal model research on tissue repair and gastrointestinal function. It is not listed on the DEA's Controlled Substances schedule. It has no FDA-approved indication. It is not recognized as a dietary supplement under DSHEA.
Under FDA authority, a substance becomes a regulated drug when it is intended to diagnose, cure, treat, mitigate, or prevent disease — or to affect the structure or function of the body. BPC-157, when sold for human administration, falls under this definition. That makes it an unapproved drug, not a freely available compound.
The absence of DEA scheduling creates a common misreading: "not scheduled" gets read as "legal." What it actually means is that BPC-157 doesn't carry the criminal exposure of a scheduled substance. It doesn't mean the FDA lacks authority over it.
For a detailed overview of the research on BPC-157, see the BPC-157 compound profile and the BPC-157 research guide.
Track 1: the 503A compounding pharmacy route
503A compounding pharmacies are state-licensed facilities permitted to prepare compounded medications for individual patients with a valid prescription from a licensed prescriber. Under this framework, a physician, nurse practitioner, or other authorized prescriber can order BPC-157 for a specific patient with a documented clinical rationale.
What the 503A track requires:
- A valid prescription from a licensed prescriber
- An active state board of pharmacy license held by the compounding facility
- Compounding for a specific patient — not bulk preparation for general sale
- State regulatory oversight via the applicable board of pharmacy
The prescriber-patient relationship creates a documented record. The pharmacy license creates an accountability structure. Neither independently guarantees product quality — but both create oversight the second track does not.
415 active US providers list BPC-157 in PeptideBase (May 2026). 85% are clinics operating through a patient-provider relationship. Only 15 providers (3.6%) are licensed 503A pharmacies dispensing directly.
To verify a pharmacy's license, search nabp.pharmacy — the National Association of Boards of Pharmacy's public database. A licensed 503A facility will appear with its license status and any disciplinary history.
Track 2: the research chemical vendor route
Research chemical vendors sell BPC-157 labeled "for laboratory use only" or "not for human consumption." This is a legal positioning mechanism — it frames the compound as a research reagent rather than a drug for human use, placing it outside the regulatory framework that applies to drugs sold for human administration.
| 503A Compounding Pharmacy | Research Chemical Vendor | |
|---|---|---|
| Prescription required | ✓ Yes | ✗ No |
| License publicly searchable | ✓ nabp.pharmacy | ✗ N/A |
| State board oversight | ✓ Yes | ✗ No |
| Quality guarantee | Neither track guarantees this | Neither track guarantees this |
The "for laboratory use only" label is not a quality statement. It describes the vendor's legal category, not the product's purity, peptide concentration, sterility, or testing rigor. A vendor can operate on this track with rigorous third-party HPLC testing — or with none.
The FDA retains authority to act against products it determines are being sold as unapproved drugs regardless of labeling. Historically, enforcement has focused on manufacturers rather than individual buyers — but that posture is neither permanent nor guaranteed.
How to tell which track your provider is on
The prescription requirement is the clearest signal. A 503A compounding pharmacy cannot legally dispense a compounded medication without a valid prescription from a licensed prescriber. A provider selling BPC-157 without requiring a prescription is not on the 503A track — regardless of how they describe themselves.
If the provider claims to be a compounding pharmacy: Search nabp.pharmacy. Licensed 503A pharmacies are listed with license status and disciplinary history. If the provider doesn't appear, ask for their state board of pharmacy license number directly.
If the provider is a clinic or telehealth platform: Verify the prescribing physician or NP's license through your state's public medical license lookup. A consultation process that produces a prescription without a documented clinical assessment is a different arrangement than a legitimate prescriber-patient relationship.
If the provider is a research chemical vendor: Focus on quality documentation: third-party COA data, HPLC test results, and the identity of the testing lab. For a full verification checklist, see How to find a legitimate peptide provider.
Why state law matters — and how it varies
Federal status is only half the picture. State pharmacy boards independently regulate compounding pharmacies, prescribing authority, and telemedicine prescribing within their borders. The practical result: access to BPC-157 through the 503A track varies meaningfully by state — even when federal rules are identical.
State-level variation affects three things:
Who can prescribe. Some states extend prescriptive authority to nurse practitioners and physician assistants independently; others require physician supervision. This affects whether a telehealth platform licensed in one state can legally prescribe to patients in another.
What out-of-state pharmacies can do. Most states require non-resident pharmacies to register with the state board before shipping compounded products into the state. A Texas 503A pharmacy shipping to a patient in California must be registered with the California State Board of Pharmacy — not just Texas.
Sterile compounding standards. States adopt and enforce USP compounding standards (particularly USP 797 for sterile preparations) independently. Some states have stricter inspection and compliance requirements than the federal floor.
BPC-157 legal status by state
The following state guides cover BPC-157's access landscape in detail — pharmacy board rules, prescribing authority, non-resident pharmacy requirements, and verified local providers.
BPC-157 in Texas
Texas is home to one of the largest compounding pharmacy industries in the country. The Texas State Board of Pharmacy (TSBP) sets detailed rules including USP 797 compliance for sterile compounding and non-resident pharmacy registration requirements. Texas allows nurse practitioners and physician assistants with prescriptive authority to prescribe compounded medications, and telemedicine prescribing is permitted under Texas Medical Board rules with specific conditions.
BPC-157 in California
California operates under the California State Board of Pharmacy with some of the most detailed non-resident pharmacy registration requirements in the country. Out-of-state pharmacies shipping to California patients must meet California-specific standards. The state has active enforcement posture on unlicensed pharmacy activity. Telehealth prescribing regulations were updated in recent years, affecting remote prescribing for compounded medications.
BPC-157 in Florida
Florida has a large and active compounding pharmacy ecosystem, with the Florida Department of Health and the Board of Pharmacy jointly overseeing compounding facilities. Florida has notable history with compounding pharmacy enforcement — it was the site of several high-profile cases in the 2010s that shaped national FDA policy. Prescribing authority for advanced practice nurses is structured differently than in Texas.
BPC-157 in New York
New York operates under the New York State Board of Pharmacy with strict requirements for both in-state and non-resident compounding pharmacies. The state has a more restrictive regulatory posture toward compounding than most southern states. Telemedicine prescribing rules are governed by the New York Department of Health and have specific requirements for establishing a valid prescriber-patient relationship.
BPC-157 in Pennsylvania
Pennsylvania is home to a significant concentration of 503A compounding pharmacies, partly reflecting its large healthcare industry. The Pennsylvania State Board of Pharmacy enforces USP compounding standards and has specific rules for sterile preparations. Prescriptive authority for certified registered nurse practitioners (CRNPs) includes prescribing compounded medications within their scope of practice.
State provider coverage
The table below shows verified BPC-157 provider counts by state in the PeptideBase directory (May 2026). Dedicated state legal guides are available for the five highest-coverage states.
| State | BPC-157 providers | State legal guide |
|---|---|---|
| Florida | 37 | BPC-157 in Florida → |
| Texas | 30 | BPC-157 in Texas → |
| California | 22 | BPC-157 in California → |
| Tennessee | 18 | Verify via: tn.gov/health |
| Arizona | 17 | Verify via: azpharmacy.gov |
| Colorado | 14 | Verify via: dpo.colorado.gov |
| New York | 13 | BPC-157 in New York → |
| Oregon | 12 | Verify via: pharmacy.oregon.gov |
| Virginia | 12 | Verify via: dhp.virginia.gov |
| Washington | 12 | Verify via: doh.wa.gov |
| Illinois | 11 | Verify via: idfpr.illinois.gov |
| Minnesota | 10 | Verify via: mn.gov/boards/pharmacy |
| Georgia | 9 | Verify via: gbp.georgia.gov |
| Pennsylvania | 8 | BPC-157 in Pennsylvania → |
For states not in the table: verify local pharmacy board rules through the NABP member board directory at nabp.pharmacy. The federal two-track framework applies nationwide — state variation is in the prescribing authority rules and non-resident pharmacy registration requirements.
BPC-157 outside the US
For international researchers: BPC-157's regulatory status varies significantly by country.
United Kingdom: BPC-157 is not a controlled substance under the Misuse of Drugs Act but is subject to MHRA oversight as an unlicensed medicine when sold for human use. The research chemical pathway exists but with different enforcement posture than the US.
Canada: Health Canada classifies BPC-157 as a drug requiring authorization for sale. It is not an approved drug. The research chemical pathway operates under similar ambiguity as the US.
Australia: The TGA (Therapeutic Goods Administration) has specifically listed BPC-157 as a controlled substance in Schedule 4 (Prescription Only Medicine) — more explicitly restricted than in the US or UK. Purchase and importation without a valid prescription and TGA authorization carries meaningful legal risk.
PeptideBase lists 30 international providers carrying BPC-157 (UK 13, Australia 8, Canada 7, Germany 1, Slovakia 1) — view international providers.
Frequently asked questions
QIs BPC-157 a controlled substance in the US?
No. BPC-157 is not listed on the DEA's Controlled Substances schedule. However, it is classified as an unapproved drug under FDA authority when sold for human use. Not being scheduled is not the same as being freely legal for human administration — the two designations address different regulatory questions.
QCan a US compounding pharmacy legally make BPC-157?
A 503A compounding pharmacy can compound BPC-157 for an individual patient with a valid prescription from a licensed prescriber. The pharmacy must hold an active state board license, and the compound must be prepared for a specific patient rather than in bulk. Notably, BPC-157 is not currently on the FDA's approved bulk drug substances list — this creates legal uncertainty for pharmacies and is an active area of regulatory discussion.
QWhat does "for laboratory use only" actually mean?
It's a legal labeling mechanism that positions the product as a research reagent rather than a drug for human use — affecting which regulatory framework applies to the vendor. It is not a statement about product quality, purity, or compliance with any testing standard. Two vendors can use this label and have entirely different quality control practices.
QDoes state law affect what I can legally receive?
Yes, indirectly. If a pharmacy ships a compounded product to you without being registered with your state's board of pharmacy, that pharmacy may be violating your state's pharmacy laws — even if the product itself is not a controlled substance. This is a separate issue from federal scheduling.
QWhy do most sources give a simple yes or no on BPC-157's legal status?
Because collapsing two distinct regulatory frameworks into a single verdict is simpler. A "yes, it's legal" answer typically refers to the research chemical track — BPC-157 is not scheduled, and buyer-level enforcement has not been a focus. A "gray area" answer reflects the FDA's authority over unapproved drugs. Both framings are accurate within their specific context. The more useful answer is: which track is your provider on, and what does that mean for oversight?
QHow do I find a provider using the 503A compounding route?
Start by filtering for clinic and telehealth providers in the PeptideBase directory — these operate through prescriber-patient relationships. Confirm the provider requires a telehealth or in-person consultation before dispensing, verify the prescriber's license through your state's public database, and ask which compounding pharmacy they partner with.
Educational information only — not medical advice. No dosing, protocol, or treatment advice is provided or implied.
Find BPC-157 providers in the PeptideBase directory, filterable by provider type and state: View BPC-157 providers →
Last reviewed: May 2026
The Peptide Research Digest
Get the next analysis in your inbox.
Weekly, evidence-led coverage of providers, sourcing, and compounds. No spam.
Alexandre Peterson is the founder of PeptideBase, an independent provider directory and educational research platform for the peptide space. He built PeptideBase to bring structure and transparency to a fragmented market — systematically indexing providers, mapping 100+ peptides, and creating tools that help researchers find the right starting point.